核素肾动态显像用于儿童先天性输尿管囊肿的诊断和随访

目的分析儿童先天性输尿管囊肿在^99mTc—EC肾动态显像（RDI）中的表现，并评价其临床应用价值。方法22例经泌尿系统B超、静脉肾盂造影（IVP）及手术探察确诊为肾积水或肾重复畸形合并输尿管囊肿的患儿，行利尿RDI检查，6例术后复查。分析24min内经叠加的1帧／2min系列影像，并评估随访结果。结栗输尿管囊肿在RDI系列影像中，表现为显像早期膀胱局部放射性分布缺损，后期有或无填充。随访复查病例，患肾功能提高（t=2．94，P〈0．05），2例膀胱影恢复正常。先天性输尿管囊肿RDI、B超、IVP的阳性率均为81．8％。结论先天性输尿管囊肿的RDI表现有合理的生理基础，其明确的特征性影像可为诊断提供较为准确的依据；用于随访时较B超和IVP检查有独特的优势。     

利尿肾动态显像在婴幼儿后尿道瓣膜中的应用

目的观察利尿肾动态显像(DR)在婴幼儿后尿道瓣膜中的影像表现,探讨用DR进行术后随访的评价方法.方法患先天性后尿道瓣膜的男性患儿22例,年龄2月～10岁.术前1周内行DR检查,根据DR结果对肾积水进行分度,并对术后随访结果进行评分,负值=恶化;0=无改变;1%～32%=满意;33%～65%=良好;>66%=优.结果所有病例肾盂均有放射性滞留,40只肾累及肾盏(90.9%);输尿管全段扩张显影34根(77.3%);膀胱无充盈8例,扩大1例,缩小9例.随访结果,"恶化"2肾,"无改变"6肾,"满意"3肾,"良好"3肾,"优"1肾.结论DB可观察到先天性后尿道瓣膜中上尿路各个部位较具特征性的改变,可帮助诊治;用于术后结果的评价,较为全面、准确及实用.     

利尿肾动态显像在婴幼儿后尿道瓣膜中的应用

目的观察利尿肾动态显像(DR)在婴幼儿后尿道瓣膜中的影像表现,探讨用DR进行术后随访的评价方法.方法患先天性后尿道瓣膜的男性患儿22例,年龄2月～10岁.术前1周内行DR检查,根据DR结果对肾积水进行分度,并对术后随访结果进行评分,负值=恶化;0=无改变;1%～32%=满意;33%～65%=良好;>66%=优.结果所有病例肾盂均有放射性滞留,40只肾累及肾盏(90.9%);输尿管全段扩张显影34根(77.3%);膀胱无充盈8例,扩大1例,缩小9例.随访结果,"恶化"2肾,"无改变"6肾,"满意"3肾,"良好"3肾,"优"1肾.结论DB可观察到先天性后尿道瓣膜中上尿路各个部位较具特征性的改变,可帮助诊治;用于术后结果的评价,较为全面、准确及实用.     

Analysis on the factors affecting the efficacy of 131Ⅰ remnant ablation in patients after thyroidectomy for differentiated thyroid carcinoma

Objective 131Ⅰ is the most effective treatment for thyroidal remnant ablation after thy-roidectomy in patients with differentiated thyroid carcinoma (DTC). Ways to improve its therapeutic efficacy have been a major clinical concern. This study was designed to assess the efficacy of thyroid ablation by finding out its leading factors. Methods Eighty cases of post-operative DTC patients who had undergone first 131Ⅰ remnant ablation therapy were retrospectively reviewed. The efficacy of the therapy was assessed by a diagnostic 131Ⅰ whole body follow-up scan 3- 6 months later. The ablation therapy was considered to be suc-cessful only if no conceivable radioactivity was detected in the thyroidectomy bed. The χ2 test and multi-vari-ance Binary Logistic regression were used to analyze 9 variances which might affect the therapeutic efficacy, including gender, age (<45 years and ≥45 years), type of pathology (papillary or follicular carcinoma), metastasis, residual thyroid weight (low, median, high), 24 h radioiodine uptake ratio (< 10%, 10%-20%, >20%), thyroglobulin (Tg, negative or positive), thyroid stimulating hormone (TSH, <30 mU/L, 30-60 mU/L, >60 mU/L), and radioiodine dose (<1850 MBq,1850-3700 MBq, >3700 MBq). Results 131Ⅰ remnant ablation therapy was successful in 58 of 80 DTC patients (72.5%). Three variances were found to have affected the therapeutic efficacy: residual thyroid weight, 24 h radioiodine uptake ratio and 131Ⅰ dose. The corresponding intra-groups statistical difference of those 3 variances was significant by χ2 test (χ2 = 8.892, 9.528, 15.085, P = 0.012, 0.009, 0. 001), while the intra-group statistical differences of the remaining variances were insignificant (χ2 =0.486, 0. 051, 0. 322, 0. 010, 0. 006, 2. 575, all P > 0. 05). All 9 variances were analyzed by the multi-variance Binary Logistic regression model through for-ward stepwise. The variance of residual thyroid weight (X1) and 131Ⅰ dose (X2) were finally selected as the 2 key parameters in the formula, P=e(-0.865-0.868X1+1.677X2)/[1-e(-0.865-0.868X1+1.677X2)] , by the Binary Logistic regression analysis (Wald values were 3.752 and9. 130, P=0.049, 0.003). Conclusions The efficacy of 131Ⅰ ablation of thyroidal remnant in post-operative DTC patients was mainly determined by the re-sidual thyroid weight and the therapeutic 131Ⅰ dose. The other 7 factors included in this study were not found to be statistically significant.     

Analysis on the factors affecting the efficacy of 131Ⅰ remnant ablation in patients after thyroidectomy for differentiated thyroid carcinoma

Objective 131Ⅰ is the most effective treatment for thyroidal remnant ablation after thy-roidectomy in patients with differentiated thyroid carcinoma (DTC). Ways to improve its therapeutic efficacy have been a major clinical concern. This study was designed to assess the efficacy of thyroid ablation by finding out its leading factors. Methods Eighty cases of post-operative DTC patients who had undergone first 131Ⅰ remnant ablation therapy were retrospectively reviewed. The efficacy of the therapy was assessed by a diagnostic 131Ⅰ whole body follow-up scan 3- 6 months later. The ablation therapy was considered to be suc-cessful only if no conceivable radioactivity was detected in the thyroidectomy bed. The χ2 test and multi-vari-ance Binary Logistic regression were used to analyze 9 variances which might affect the therapeutic efficacy, including gender, age (<45 years and ≥45 years), type of pathology (papillary or follicular carcinoma), metastasis, residual thyroid weight (low, median, high), 24 h radioiodine uptake ratio (< 10%, 10%-20%, >20%), thyroglobulin (Tg, negative or positive), thyroid stimulating hormone (TSH, <30 mU/L, 30-60 mU/L, >60 mU/L), and radioiodine dose (<1850 MBq,1850-3700 MBq, >3700 MBq). Results 131Ⅰ remnant ablation therapy was successful in 58 of 80 DTC patients (72.5%). Three variances were found to have affected the therapeutic efficacy: residual thyroid weight, 24 h radioiodine uptake ratio and 131Ⅰ dose. The corresponding intra-groups statistical difference of those 3 variances was significant by χ2 test (χ2 = 8.892, 9.528, 15.085, P = 0.012, 0.009, 0. 001), while the intra-group statistical differences of the remaining variances were insignificant (χ2 =0.486, 0. 051, 0. 322, 0. 010, 0. 006, 2. 575, all P > 0. 05). All 9 variances were analyzed by the multi-variance Binary Logistic regression model through for-ward stepwise. The variance of residual thyroid weight (X1) and 131Ⅰ dose (X2) were finally selected as the 2 key parameters in the formula, P=e(-0.865-0.868X1+1.677X2)/[1-e(-0.865-0.868X1+1.677X2)] , by the Binary Logistic regression analysis (Wald values were 3.752 and9. 130, P=0.049, 0.003). Conclusions The efficacy of 131Ⅰ ablation of thyroidal remnant in post-operative DTC patients was mainly determined by the re-sidual thyroid weight and the therapeutic 131Ⅰ dose. The other 7 factors included in this study were not found to be statistically significant.     

Graves病患者131I治疗前、后TRAb和FT3、FT4、TSH的变化及其临床意义

甲状腺疾病是临床上一种常见的内分泌疾病,各年龄均可发生.Graves病是临床上最常见的甲状腺疾病,尤以女性多发,男女之比为1:4～6[1].人血清促甲状腺素受体抗体(TRAb)是自身免疫性甲状腺疾病患者体内存在的影响甲状腺滤泡功能和生长的自身抗体,在Graves病中起重要作用.     

分化型甲状腺癌^131I疗效影响因素分析

目的对分化型甲状腺癌（DTC）术后患者实施放射性碘（^131I）清除残余甲状腺（清甲）治疗,分析影响清甲效果的相关因素。方法收集DTC术后接受^131I清甲治疗患者的临床资料。采用BinaryLogistic回归分析和x^2检验,分析患者性别和年龄、DTC的病理学类型和有无转移、甲状腺残余组织大小、血清促甲状腺激素（TSH）水平、甲状腺摄碘率和^131I治疗剂量对清甲疗效的影响。结果共收集183例患者资料,其中一次清甲完全者109例,占59．56％。BinaryLogistic回归分析表明,残余甲状腺大小和^131I治疗剂量分别是影响清甲效果的主要因素（Wald=8．59,P=0．003;Wald=6．40,P=0．011）。x^2检验结果显示,与血清TSH水平≥30uIU／mL患者比较,血清TSH水平〈30uIU／mL患者的清甲效果较差（x^2=7．291,P=0．007）;而血清TSH水平〈60uIU／mL与≥60uIU／mL患者间清甲效果比较,差异无统计学意义（P〉0．05）。结论在分化型甲状腺癌患者的^131I清甲治疗中,残余甲状腺大小和^131I治疗剂量是影响清甲效果的主要因素。血清TSH水平≥30uIU／mL者的清甲疗效较好,而过高的血清TSH水平则并不能使清甲效果进一步提高。     

分化型甲状腺癌131Ⅰ治疗中多种核素显像的联合应用

目的 探讨提高分化型甲状腺癌(DTC)复发灶或转移灶检出率的最优化核素显像方法 .方法 对89例DTC患者的临床资料进行回顾性分析.核素显像方法 包括血清甲状腺球蛋白(Tg)检查结合放射性碘(131Ⅰ)治疗剂量全身显像、99mTc-MIBI肿瘤显像和18F-FDG带符合线路的SPECT/CT全身显像,对三种核素显像的结果 进行对比分析.结果 131Ⅰ治疗剂量全身显像、99mTc-MIBI 肿瘤显像和18F-FDG带符合线路的SPECT/CT全身显像的灵敏度分别为83.05%、79.66%和16.95%.结论 99mTc-MIBI肿瘤显像和18F-FDG带符合线路的SPECT/CT全身显像作为补充检查手段,可弥补血清Tg检查结合131Ⅰ全身显像的局限性,对DTC患者复发灶或转移灶的检出、疗效评估及进一步治疗方案的制定具有重要意义.     

Analysis on the factors affecting the efficacy of 131Ⅰ remnant ablation in patients after thyroidectomy for differentiated thyroid carcinoma

Objective 131Ⅰ is the most effective treatment for thyroidal remnant ablation after thy-roidectomy in patients with differentiated thyroid carcinoma (DTC). Ways to improve its therapeutic efficacy have been a major clinical concern. This study was designed to assess the efficacy of thyroid ablation by finding out its leading factors. Methods Eighty cases of post-operative DTC patients who had undergone first 131Ⅰ remnant ablation therapy were retrospectively reviewed. The efficacy of the therapy was assessed by a diagnostic 131Ⅰ whole body follow-up scan 3- 6 months later. The ablation therapy was considered to be suc-cessful only if no conceivable radioactivity was detected in the thyroidectomy bed. The χ2 test and multi-vari-ance Binary Logistic regression were used to analyze 9 variances which might affect the therapeutic efficacy, including gender, age (<45 years and ≥45 years), type of pathology (papillary or follicular carcinoma), metastasis, residual thyroid weight (low, median, high), 24 h radioiodine uptake ratio (< 10%, 10%-20%, >20%), thyroglobulin (Tg, negative or positive), thyroid stimulating hormone (TSH, <30 mU/L, 30-60 mU/L, >60 mU/L), and radioiodine dose (<1850 MBq,1850-3700 MBq, >3700 MBq). Results 131Ⅰ remnant ablation therapy was successful in 58 of 80 DTC patients (72.5%). Three variances were found to have affected the therapeutic efficacy: residual thyroid weight, 24 h radioiodine uptake ratio and 131Ⅰ dose. The corresponding intra-groups statistical difference of those 3 variances was significant by χ2 test (χ2 = 8.892, 9.528, 15.085, P = 0.012, 0.009, 0. 001), while the intra-group statistical differences of the remaining variances were insignificant (χ2 =0.486, 0. 051, 0. 322, 0. 010, 0. 006, 2. 575, all P > 0. 05). All 9 variances were analyzed by the multi-variance Binary Logistic regression model through for-ward stepwise. The variance of residual thyroid weight (X1) and 131Ⅰ dose (X2) were finally selected as the 2 key parameters in the formula, P=e(-0.865-0.868X1+1.677X2)/[1-e(-0.865-0.868X1+1.677X2)] , by the Binary Logistic regression analysis (Wald values were 3.752 and9. 130, P=0.049, 0.003). Conclusions The efficacy of 131Ⅰ ablation of thyroidal remnant in post-operative DTC patients was mainly determined by the re-sidual thyroid weight and the therapeutic 131Ⅰ dose. The other 7 factors included in this study were not found to be statistically significant.     

分化型甲状腺癌131I治疗中多种核素显像的联合应用

目的 探讨提高分化型甲状腺癌(DTC)复发灶或转移灶检出率的最优化核素显像方法 .方法 对89例DTC患者的临床资料进行回顾性分析.核素显像方法 包括血清甲状腺球蛋白(Tg)检查结合放射性碘(131Ⅰ)治疗剂量全身显像、99mTc-MIBI肿瘤显像和18F-FDG带符合线路的SPECT/CT全身显像,对三种核素显像的结果 进行对比分析.结果 131Ⅰ治疗剂量全身显像、99mTc-MIBI 肿瘤显像和18F-FDG带符合线路的SPECT/CT全身显像的灵敏度分别为83.05%、79.66%和16.95%.结论 99mTc-MIBI肿瘤显像和18F-FDG带符合线路的SPECT/CT全身显像作为补充检查手段,可弥补血清Tg检查结合131Ⅰ全身显像的局限性,对DTC患者复发灶或转移灶的检出、疗效评估及进一步治疗方案的制定具有重要意义.